MyoKardia, Inc. (MYOK)
Stock Price:
$103.40 USD
3.13 (3.12%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $104.00 +0.60 (0.58%) Aug 7, 5:17 PM
Key Info
| Market Cap |
5.45B |
| Revenue (ttm) |
12.40M |
| Net Income (ttm) |
-334.02M |
| Shares Out |
53.00M |
| EPS (ttm) |
-7.07 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$103.40 |
| Previous Close |
$100.27 |
| Change ($) |
3.13 |
| Change (%) |
3.12% |
| Day's Open |
100.01 |
| Day's Range |
99.61 - 104.22 |
| Day's Volume |
312,214 |
| 52-Week Range |
42.65 - 126.30 |
More Stats
| Market Cap |
5.45B |
| Enterprise Value |
4.58B |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
53.00M |
| Float |
51.55M |
| EPS (basic) |
-7.1 |
| EPS (diluted) |
-7.07 |
| FCF / Share |
-6.12 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.10M |
| Short Ratio |
10.84 |
| Short % of Float |
33.28% |
| Beta |
2.17 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
439.60 |
| PB Ratio |
5.83 |
| Revenue |
12.40M |
| Operating Income |
-342.89M |
| Net Income |
-334.02M |
| Free Cash Flow |
-304.99M |
| Net Cash |
868.53M |
| Net Cash / Share |
16.47 |
| Gross Margin |
-1,823.96% |
| Operating Margin |
-2,765.27% |
| Profit Margin |
n/a |
| FCF Margin |
-2,459.63% |
| ROA |
-26.54% |
| ROE |
-44.75% |
| ROIC |
-112.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (11)
| Buy |
11 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$137.45*
(32.93% upside)
Low
121
Current: $103.40
High
188
Target: 137.45
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | 33.56 | 11.44 | 41.97 | 14.20 | 5.92 | - |
| Revenue Growth | - | 193.29% | -72.74% | 195.59% | 140.01% | - | - |
| Gross Profit | - | 33.56 | 11.44 | 41.97 | 14.20 | 5.92 | - |
| Operating Income | -288 | -73.65 | -58.67 | -10.53 | -23.21 | -17.22 | -13.63 |
| Net Income | -276 | -67.70 | -57.01 | -10.38 | -22.95 | -16.83 | -12.70 |
| Shares Outstanding | 44.77 | 38.39 | 32.83 | 27.48 | 6.29 | 1.76 | 1.17 |
| Earnings Per Share | -6.17 | -1.76 | -1.74 | -0.38 | -4.48 | -11.30 | -11.98 |
| Operating Cash Flow | -242 | -64.82 | -9.84 | -20.86 | -32.10 | 13.66 | -12.53 |
| Capital Expenditures | -3.26 | -3.37 | -1.51 | -1.08 | -1.31 | -0.72 | -1.17 |
| Free Cash Flow | -245 | -68.19 | -11.35 | -21.94 | -33.41 | 12.94 | -13.70 |
| Cash & Equivalents | 418 | 317 | 257 | 140 | 112 | 43.65 | 1.91 |
| Total Debt | 0.38 | - | - | - | - | - | - |
| Net Cash / Debt | 418 | 317 | 257 | 140 | 112 | 43.65 | 1.91 |
| Assets | 456 | 407 | 283 | 201 | 117 | 46.89 | 4.70 |
| Liabilities | 49.82 | 36.69 | 52.13 | 55.92 | 22.71 | 32.21 | 2.56 |
| Book Value | 406 | 371 | 231 | 145 | 93.87 | -36.91 | -17.25 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
MyoKardia, Inc. |
| Country |
United States |
| Employees |
235 |
| CEO |
Anastasios E. Gianakakos |
Stock Information
| Ticker Symbol |
MYOK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MYOK |
| IPO Date |
October 29, 2015 |
Description
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. The company also develops MYK-491, an orally-administered small molecule, which is in Phase IIa clinical trial that is designed to restore normal cardiac muscle contractility in the diseased dilated cardiomyopathy (DCM) heart. Its preclinical programs include MYK-224, a HCM-targeting candidate that is designed to reduce excess cardiac contractility and enhance diastolic function; LUS-1, which is used to counteract a muscle abnormality that results in impaired relaxation of the left ventricle; and ACT-1 targeting genetic DCM due to sarcomeric mutations and impaired calcium regulation. The company has a collaboration with 23andMe, Inc., a consumer genetics and research company; and a strategic collaboration and license agreement with Fulcrum Therapeutics, Inc. to discover, develop and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Myokardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.